The Promise and Reality of NGTs

Watch and Listen to 2022’s Summer Special episode

Our Transformation Talks Summer Special is here!

Next Generation Therapies (NGTs) currently in development will deliver treatments that address the underlying cause of diseases, disrupt the biopharmaceutical environment, and offer a life-long solution to patients. They create unprecedented opportunities for patients and will be measurable in lives saved, disabilities reduced, and overall quality of life improvements. However, along with these benefits come unprecedented challenges for insurance coverage, reimbursement, and payment.

Tune in to learn about risks and challenges in developing NGTs, bringing them to the market, and how NGTs can change patients’ lives once their value is understood and correctly attributed by the decision makers / payers.

This special episode is not only be available in audio format but also in video and features a stellar group of guests:

  • Andrea Mantovani – Vice President, Global Market Access and Pricing, Alira Health
  • Oswald Bentinck – Vice President – Head of Market Access EMEA, Novartis Gene Therapies
  • Pietro Sternini – Executive Director, Gene Therapy Market Access & Marketing Lead, EMEA, Astellas Gene Therapies
Watch the episode “The Promise and Reality of NGTs”:

Listen to the episode:

The episode “The Promise and Reality of Next Generation Therapies” is also available on the following platforms:

Google Podcasts      Spotify

Multimedia
Category:
Published on:
July 20, 2022
Meet our speakers:
Andrea Mantovani

Andrea Mantovani

Vice President, Global Market Access and Pricing, Alira Health
Oswald Bentinck headshot

Oswald Bentinck

Vice President - Head of Market Access EMEA, Novartis Gene Therapies
Pietro Sternini headshot

Pietro Sternini

Executive Director, Gene Therapy Market Access & Marketing Lead, EMEA, Astellas Gene Therapies
Meet our host:
Kenny Carberry

Kenny Carberry

Director, Clinical Development, Alira Health

Related news

Blog March 20, 2023
The State of Market Access in Italy 2023
To learn about the state of market access in Italy today, we spoke with Giovanni Firenze, Director of Market Access Italy for Alira Health, who attended the recent 2023 Conferenza Nazionale(...)
Drug Development Market Access Pharma
Events March 6, 2023
World EPA Congress 2023
We are pleased to share that we will be participating in World EPA Congress 2023 as speakers and sponsors. World Evidence, Pricing and Access Congress is Europe’s largest congress(...)
Biotech Market Access Pharma Real-World Evidence
Blog March 6, 2023
Market Access in Catalonia: 2022 Trends and What’s Next
Alira Health contributed to the recently published 2022 BioRegion Report, the most extensive analysis of the assets, achievements, and trends in the life sciences and healthcare sector(...)
Biotech Market Access MedTech
Events February 21, 2023
sTARTUp Day 2023
We are pleased to announce that we will be joining sTARTUp Day 2023 as speakers. This unique event will bring together startup-minded people to celebrate entrepreneurship in the city of Tartu.
Healthcare Technology Market Access Spain Startups
News February 21, 2023
Access and reimbursement pathways for digital health solutions and IVD devices
Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular(...)
Diagnotics Digital Therapeutics Market Access Regulatory
News February 13, 2023
Alira Health Contributes to 2022 Bioregion Report on the Future of Catalan Life Sciences
We are pleased to announce that Alira Health is a key contributor to the just released 2022 Bioregion Report, the benchmark study that analyzes the life sciences and healthcare sector in Catalonia.
Market Access
Events February 9, 2023
2022 BioRegion Report Presentation
We are excited to announce that we will be joining as speakers at the annual presentation of the 2022 BioRegion of Catalonia Report.
BioRegion Market Access
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.